Immunotech Biopharm (HKSE:06978) Total Current Assets: HK$189.56 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06978 Immunotech Biopharm Ltd HKSE:06978
17 GF Score
Price HK$0.39
! 4 Warning Signs
View Full Analysis

What is Immunotech Biopharm Total Current Assets?

Immunotech Biopharm HKSE:06978 17 Total Current Assets is HK$189.56 Mil as of Dec. 2025. GuruFocus rates HKSE:06978 with a GF Score™ of 17/100. The stock has 4 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Immunotech Biopharm's total current assets for the quarter that ended in Dec. 2025 was HK$189.56 Mil.

Immunotech Biopharm  (HKSE:06978) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Immunotech Biopharm's Liquidation Value for the quarter that ended in Dec. 2025 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=170.754-685.089+0.75 * 0+0.5 * 4.99
=-511.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunotech Biopharm Total Current Assets Related Terms

Immunotech Biopharm Total Current Assets Historical Data

* Premium members only.

The historical data trend for Immunotech Biopharm's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunotech Biopharm Total Current Assets Chart

Immunotech Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Assets
Get a 7-Day Free Trial 504.73 131.90 233.95 93.42 189.56

Immunotech Biopharm Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 233.95 194.67 93.42 44.56 189.56
HKSE:06978
17GF Score
Immunotech Biopharm Ltd HKSE:06978
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunotech Biopharm Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Immunotech Biopharm's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=170.754+13.63+4.99+0.18800000000002
=189.56

Immunotech Biopharm's Total Current Assets for the quarter that ended in Dec. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=170.754+13.63+4.99+0.18800000000002
=189.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of HK$189.56 Mil mean?
Immunotech Biopharm (HKSE:06978) has a Total Current Assets of HK$189.56 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Immunotech Biopharm and its competitors.
Is Immunotech Biopharm's Total Current Assets too high?
Immunotech Biopharm's current Total Current Assets is HK$189.56 Mil. Overall, Immunotech Biopharm has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Immunotech Biopharm's Total Current Assets compare to VRTX and REGN?
Immunotech Biopharm's Total Current Assets of HK$189.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Immunotech Biopharm and its competitors. Immunotech Biopharm's current Total Current Assets is HK$189.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunotech Biopharm stock overvalued right now?
Immunotech Biopharm (HKSE:06978) has a current Total Current Assets of HK$189.56 Mil. The current Total Current Assets is HK$189.56 Mil. Immunotech Biopharm's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Immunotech Biopharm (HKSE:06978), the current Total Current Assets is HK$189.56 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immunotech Biopharm Business Description

Address No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
17GF Score

Get the complete analysis for HKSE:06978

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.39
Price